Fibroblast growth factor receptor 3D receptor
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 5: | Line 5: | ||
*FGFR1 | *FGFR1 | ||
| + | |||
| + | **[[8jqi]] – hFGFR1 + PLC gamma – human – Cryo EM<br /> | ||
*''FGFR1 tyrosine kinase domain (TKD) residues 458-765'' | *''FGFR1 tyrosine kinase domain (TKD) residues 458-765'' | ||
| - | **[[4uwy]] – hFGFR1 TKD | + | **[[4uwy]] – hFGFR1 TKD <br /> |
| - | **[[1fgk]], [[3kxx]], [[3ky2]], [[4rwi]], [[5flf]] – hFGFR1 TKD (mutant) | + | **[[1fgk]], [[3kxx]], [[3ky2]], [[4rwi]], [[5flf]] – hFGFR1 TKD (mutant) <br /> |
| - | **[[4wun]], [[5am6]], [[5ew8]], [[5o49]], [[5o4a]], [[6mzw]], [[ | + | **[[4wun]], [[5am6]], [[5ew8]], [[5o49]], [[5o4a]], [[6c1o]], [[6mzq]], [[6mzw]], [[8xlo]], [[8xlq]], [[8xz7]], [[8y22]], [[9cd5]] – hFGFR1 TKD + inhibitor <br /> |
| - | **[[1agw]], [[1fgi]], [[2fgi]], [[3c4f]], [[3js2]], [[3rhx]], [[4f63]], [[4f64]], [[4f65]], [[3tt0]], [[4nk9]], [[4nka]], [[4nks]], [[5b7v]], [[5am7]], [[4rwj]], [[4rwk]], [[4rwl]], [[4uwb]], [[4uwc]], [[4zsa]], [[5uq0]], [[5vnd]], [[5ur1]], [[6c18]], [[6c19]], [[6c1b]], [[6c1c]], [[5z0s]], [[6agx]], [[6itj]], [[6nvl]], [[6p68]], [[6p69]], [[7ozb]], [[7ozd]], [[7ozf]], [[7ozy]], [[7wcw]] – hFGFR1 TKD (mutant) + inhibitor <br /> | + | **[[1agw]], [[1fgi]], [[2fgi]], [[3c4f]], [[3js2]], [[3rhx]], [[4f63]], [[4f64]], [[4f65]], [[3tt0]], [[4nk9]], [[4nka]], [[4nks]], [[5b7v]], [[5am7]], [[4rwj]], [[4rwk]], [[4rwl]], [[4uwb]], [[4uwc]], [[4zsa]], [[5uq0]], [[5vnd]], [[5ur1]], [[6c18]], [[6c19]], [[6c1b]], [[6c1c]], [[5z0s]], [[6agx]], [[6itj]], [[6nvl]], [[6p68]], [[6p69]], [[7ozb]], [[7ozd]], [[7ozf]], [[7ozy]], [[7wct]], [[7wcw]], [[7wcx]] – hFGFR1 TKD (mutant) + inhibitor <br /> |
| - | **[[5zv2]], [[7wcl]] – hFGFR1 TKD (mutant) + anti-cancer drug<br /> | + | **[[8yki]] – hFGFR1 TKD + anti-cancer drug<br /> |
| + | **[[5zv2]], [[7wcl]], [[8jmz]] – hFGFR1 TKD (mutant) + anti-cancer drug<br /> | ||
**[[3krj]] – hFGFR1 TKD residues 538-678, 753-922 (mutant) + inhibitor <br /> | **[[3krj]] – hFGFR1 TKD residues 538-678, 753-922 (mutant) + inhibitor <br /> | ||
**[[1xr0]] – hFGFR1 residues 409-430 + FGFR signaling adaptor N terminal - NMR<br /> | **[[1xr0]] – hFGFR1 residues 409-430 + FGFR signaling adaptor N terminal - NMR<br /> | ||
| Line 33: | Line 36: | ||
**[[1evt]] – hFGFR1 LBD D2,D3 + hFGF1 <br /> | **[[1evt]] – hFGFR1 LBD D2,D3 + hFGF1 <br /> | ||
**[[1fq9]] – hFGFR1 (mutant) LBD D2,D3 + hFGF2 (mutant) + HS<br /> | **[[1fq9]] – hFGFR1 (mutant) LBD D2,D3 + hFGF2 (mutant) + HS<br /> | ||
| - | **[[5w21]] – hFGFR1 LBD D2,D3 + hFGF23 + klotho <br /> | + | **[[5w21]]. [[7ysh]] – hFGFR1 LBD D2,D3 + hFGF23 + klotho <br /> |
*FGFR2 | *FGFR2 | ||
| Line 46: | Line 49: | ||
**[[3cly]], [[6v6q]] – hFGFR2 TKD (mutant) with PTR + ACP <br /> | **[[3cly]], [[6v6q]] – hFGFR2 TKD (mutant) with PTR + ACP <br /> | ||
**[[5eg3]] – hFGFR2 TKD (mutant) with PTR + ACP + phospholipase C γ<br /> | **[[5eg3]] – hFGFR2 TKD (mutant) with PTR + ACP + phospholipase C γ<br /> | ||
| - | **[[3ri1]], [[6lvk]], [[6lvl]], [[8e1x]] – hFGFR2 TKD + inhibitor<br /> | + | **[[3ri1]], [[6lvk]], [[6lvl]], [[8e1x]], [[8h75]], [[8stg]], [[8u1f]], [[8w2x]], [[8w38]], [[8w3d]] – hFGFR2 TKD + inhibitor<br /> |
| - | **[[7kia]], [[7kie]] – hFGFR2 TKD (mutant) + inhibitor<br /> | + | **[[7kia]], [[7kie]], [[8swe]], [[9u3n]] – hFGFR2 TKD (mutant) + inhibitor<br /> |
| - | * | + | *FGFR2 ligand-binding domain 134-249 |
**[[3dar]], [[3caf]], [[3euu]] – hFGFR2 LBD D2 150-249<br /> | **[[3dar]], [[3caf]], [[3euu]] – hFGFR2 LBD D2 150-249<br /> | ||
| + | **[[8om6]] – hFGFR2 LBD D2 (mutant) <br /> | ||
**[[1wvz]] – hFGFR2 LBD D2 - NMR<br /> | **[[1wvz]] – hFGFR2 LBD D2 - NMR<br /> | ||
**[[4wv1]] – hFGFR2 LBD D2 + antibody<br /> | **[[4wv1]] – hFGFR2 LBD D2 + antibody<br /> | ||
| Line 73: | Line 77: | ||
**[[2lzl]] – hFGFR3 residues 357-399 – NMR<br /> | **[[2lzl]] – hFGFR3 residues 357-399 – NMR<br /> | ||
**[[4k33]] – hFGFR3 TKD (mutant)<br /> | **[[4k33]] – hFGFR3 TKD (mutant)<br /> | ||
| - | **[[6lvm]], [[7dhl]] – hFGFR3 TKD + inhibitor<br /> | + | **[[6lvm]], [[7dhl]], [[8udt]], [[8udu]], [[8udv]], [[9cd7]], [[9d1x]] – hFGFR3 TKD + inhibitor<br /> |
**[[6pnx]] – hFGFR3 TKD (mutant) + ACP<br /> | **[[6pnx]] – hFGFR3 TKD (mutant) + ACP<br /> | ||
| Line 79: | Line 83: | ||
**[[1ry7]] – hFGFR3 LBD + hFGF1<br /> | **[[1ry7]] – hFGFR3 LBD + hFGF1<br /> | ||
| + | **[[7ysu]] – hFGFR3 LBD D2,D3 + hFGF23 + klotho – Cryo EM <br /> | ||
*FGFR4 | *FGFR4 | ||
| Line 86: | Line 91: | ||
**[[4tye]], [[4tyg]], [[4tyi]], [[4tyj]] – hFGFR4 TKD <br /> | **[[4tye]], [[4tyg]], [[4tyi]], [[4tyj]] – hFGFR4 TKD <br /> | ||
**[[4qqj]], [[4qqt]] – hFGFR4 TKD (mutant) <br /> | **[[4qqj]], [[4qqt]] – hFGFR4 TKD (mutant) <br /> | ||
| - | **[[5jkg]], [[5nwz]], [[5nud]], [6nvg]], [[6nvh]], [[6nvi]], [[6nvj]], [[6nvk]], [[6v9c]], [[7dtz]], [[7f3m]], [[7v29]], [[7vjl]], [[7wct]], [[7ybo]], [[7yc1]], [[7yc3]] – hFGFR4 TKD + inhibitor<br /> | + | **[[5jkg]], [[5nwz]], [[5nud]], [[6nvg]], [[6nvh]], [[6nvi]], [[6nvj]], [[6nvk]], [[6v9c]], [[7dtz]], [[7f3m]], [[7v29]], [[7vjl]], [[7wct]], [[7ybo]], [[7yc1]], [[7yc3]], [[8w5c]] – hFGFR4 TKD + inhibitor<br /> |
| + | **[[7tyd]] – hFGFR4 TKD + protein inhibitor<br /> | ||
**[[6yi8]] – hFGFR4 TKD + drug<br /> | **[[6yi8]] – hFGFR4 TKD + drug<br /> | ||
| - | ** | + | **[[5xff]], [[5xfj]], [[6iuo]], [[6iup]], [[6jpe]], [[6jpj]], [[7v29]], [[7wcw]], [[7wcx]], [[7ybp]], [[7ybx]], [[8kh6]], [[8kh7]], [[8kh8]], [[8kh9]] – hFGFR4 TKD (mutant) + inhibitor<br /> |
**[[4qrc]], [[4r6v]], [[4qqc]], [[4qq5]], [[4uxq]], [[4xcu]] – hFGFR4 TKD (mutant) + irreversible inhibitor<br /> | **[[4qrc]], [[4r6v]], [[4qqc]], [[4qq5]], [[4uxq]], [[4xcu]] – hFGFR4 TKD (mutant) + irreversible inhibitor<br /> | ||
| + | |||
| + | *''FGFR4 LBD'' | ||
| + | |||
**[[6j6y]] – hFGFR4 LBD D2 + antibody<br /> | **[[6j6y]] – hFGFR4 LBD D2 + antibody<br /> | ||
**[[7n1j]], [[7tyd]] – hFGFR4 LBD D3 + binder<br /> | **[[7n1j]], [[7tyd]] – hFGFR4 LBD D3 + binder<br /> | ||
Current revision
3D structures of fibroblast growth factor receptor
Updated on 03-July-2025
